Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced today that the New Drug Application (NDA) for its novel, orally administered, highly selective, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback